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Microbeam radiation therapy (MRT) is a developing radiotherapy, based on the use of beams only few 
tens of micrometer wide, generated by synchrotron X-ray sources. The spatial fractionation of the 
homogenous beam into an array of microbeams is possible using a multislit collimator (MSC), i.e. a 
machined metal block with regular apertures. Dosimetry in MRT is challenging and previous works still 
show differences between calculated and experimental dose profiles of 10% - 30%, which are not 25 
acceptable for a clinical implementation of the treatment. The interaction of the X-rays with the MSC may 
contribute to the observed discrepancies; the present study therefore investigates the dose contribution 
due to radiation interaction with the MSC inner walls and radiation leakage of the MSC.  
Dose distributions inside a water-equivalent phantom were evaluated for different field sizes and three 
typical spectra used for MRT studies at the European Synchrotron Biomedical beamline ID17. Film 30 
dosimetry was utilized to determine the contribution of radiation interaction with the MSC inner walls; 
Monte Carlo simulations were implemented to calculate the radiation leakage contribution. 
Both factors turned out to be relevant for the dose deposition, especially for small fields. Photons 
interacting with the MSC walls may bring up to 16% more dose in the valley regions, between the 
microbeams. Depending on the chosen spectrum, the radiation leakage close to the phantom surface can 35 
contribute up to 50% of the valley dose for a 5 × 5 mm² field.  
Our study underlines that a detailed characterization of the MSC must systematically be performed and 
accurate MRT dosimetry protocols must include the contribution of radiation leakage and radiation 






The idea to spatially fractionate the radiation field into a grid of smaller beams of about 1 mm size to 
reduce side effects in the patients’ skin (Laissue et al., 2012) was introduced soon after the beginning of 
X-ray radiation therapy (1957). The advent of synchrotron X-ray sources and technological progress made 45 
possible the creation of microbeams, only few tens of micrometers wide, which proved to be extremely 
effective in radiotherapy. The fundamental biological effect at the basis of microbeam radiation therapy 
(MRT) is the dose-volume effect, i.e. the capability of healthy tissues to tolerate a high dose of radiation if 
it is confined into small volumes (Zeman et al., 1961). 
In the past decades, a large body of pre-clinical work has shown the potential and enhanced effectiveness 50 
of MRT compared to other conventional techniques based on homogeneous radiation fields (Laissue et 
al., 1998, 2013; Schültke et al., 2008; Slatkin et al., 2007; Van Der Sanden et al., 2010; Smyth et al., 2018; 
Bouchet et al., 2013; Crosbie et al., 2010; Bouchet et al., 2010; Ibahim et al., 2016, 2014; Slatkin et al., 
1992; Slatkin, Spanne et al., 1995; Fernandez-Palomo et al., 2020). While initially MRT research focused 
on applications for cancer treatment, recent studies extended to the treatment of chronic pain and 55 
epilepsies (Zippo et al., 2019; Romanelli & Bravin, 2011; Studer et al., 2015; Pouyatos et al., 2016; Anschel 
et al., 2011; Pouyatos et al., 2013). 
MRT studies were performed with arrays of 25 – 100 µm wide beams, spaced by 100 – 1000 µm (center-
to-center) to understand differences in tissues response (Bräuer-Krisch et al., 2010; Dilmanian et al., 2004; 
Serduc et al., 2009; Griffin et al., 2012; Laissue et al., 1998). The most commonly used geometry is an 60 
array of 50 µm beams with a 400 µm pitch. This array is divided into peak regions corresponding to the 
microbeams, and valley regions where the dose arises only from scattered photons inside the target. The 
ratio between peak and valley doses is called peak-to-valley dose ratio (PVDR). Typically, the valley dose 
is kept below the limit established for conventional radiotherapy, while the peak dose can be as high as 
several hundreds of grays, with dose rates up to 16 kGy/s. A steep dose gradient at the edge of peak 65 
regions is achievable using orthovoltage X-ray, with a mean energy in the order of 100 keV. Due to the 
small vertical divergence of synchrotron X-rays, radiation fields of sufficient vertical size are obtained 
scanning the target vertically through the beam, while the horizontal fan of a wiggler source allows for 
horizontal field sizes of 40 – 100 mm. 
To transform a homogeneous radiation field into a spatially fractionated array of microbeams, a multislit 70 
collimator (MSC) is placed in front of the target. The first MSC at fixed geometry was realized alternating 
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Au and Al foils (Slatkin, Dilmanian et al., 1995; Archer, 1998; Bräuer-Krisch et al., 2003) but it was soon 
replaced by a more versatile Tecomet® model able to define microbeams of variable width (Bräuer-Krisch 
et al., 2005). Improved machining techniques allowed the realization of more precise and accurate 
apertures and two of the most recent MSCs are described in the work of E. Bräuer-Krisch et al. (Bräuer-75 
Krisch et al., 2009). While variable aperture MSCs are more versatile, an MSC with fixed geometry is easier 
to align and to control during an experiment. Nowadays, MSCs are typically made of a tungsten-based 
alloy, machined out of a single piece or assembled using individual blades to obtain the desired width and 
spacing of the microbeam array.  
At present, there are several dedicated beamlines for MRT research in operation world-wide, at the ESRF 80 
(Grenoble, France), the Australian Synchrotron (Clayton, Australia), SPring-8 (Hyogo, Japan), and the 
Canadian Light Source (Saskatoon, Canada). In parallel, compact radiation sources with adequate 
characteristics are under development (Bartzsch et al., 2016; Hadsell et al., 2014; Bartzsch et al., 2020). 
The Australian Synchrotron and the ESRF move forward towards phase-I clinical trials and therefore 
undertake significant efforts to develop reliable dosimetry protocols capable to predict the absorbed dose 85 
in the target. Differences between calculated and measured doses in MRT are often between 10 and 30%, 
still significantly higher than the differences considered acceptable in conventional radiotherapy. One 
possible source of this discrepancy is the interaction of X-rays with the MSC which has never been 
investigated in detail. The slightly divergent photon beam interacts with the inner surfaces of the MSC, 
giving rise to scattering effects. Furthermore, the metal blades may be not able to completely stop the 90 
incident radiation and a significant amount of photons might be transmitted.  
So far, only a partial study of these two aspects have been conducted. A Monte Carlo (MC) model of the 
MSC was presented by Nettelbeck et al., which included the influence of the beam divergence on the 
penumbra at the edge of the microbeams (Nettelbeck et al., 2009) but an experimental evaluation was 
not performed. Moreover, the study of possible radiation leakage was omitted due to, at the time, long 95 
simulations required to decrease the uncertainty in the valley dose. Martínez-Rovira et al. developed a 
MC model of the ID17 beamline using Shadow and Penelope codes (Martínez-Rovira et al., 2012). The 
simulated PVDR were often higher than experimental values, with differences above 10%. Bartzsch et al. 
performed MC simulations with the Geant4 toolkit including synchrotron beam polarization and 
suggested an approximate model for beam divergence and MSC leakage (Bartzsch et al., 2014). The 100 
influence of the photon interactions with the MSC inner walls was observed by Fournier et al. using a 
silicon strip detector (Fournier, Cornelius et al., 2016). Changing the aperture alignment by ±0.02°, the 
5 
 
detector revealed valley dose variations, but a quantitative dosimetry study was not performed. More 
recently, Ocadiz et al. have found dose differences above 25% (Ocadiz et al., 2019) when comparing film 
dosimetry with a MC hybrid dose calculation (Donzelli et al., 2018) in MRT.  105 
For the Imaging and Medical Beamline (IMBL) of the Australian Synchrotron, two MC models have been 
recently presented. A. Dipuglia et al. (Dipuglia et al., 2019) developed a detailed MC model of the entire 
IMBL, including the electron transport inside the wiggler source, for the generation of phase space files as 
input for dose calculation. L. Day et al. (Day et al., 2020) presented as well a reliable IMBL model, where 
an analytical approach is used to calculate the generated polychromatic spectrum that is used in MC 110 
simulations for the dose calculation. Both works reported convincing experimental data in support to their 
models. The approach used in this study is closer to the one proposed by L. Day et al., as the spectrum 
profile is generated by an analytical approach using XOP software (see section 2.1.1). The MSC available 
at the IMBL has similar properties to the MSC available at the ID17 beamline because both were realized 
using the same construction technique. The ID17 X-ray spectrum has an overall higher photon flux, a 115 
higher mean energy, and extends to higher photon energies than the IMBL spectrum. The detailed 
comparison between the spectra used at the ID17 beamline and the IMBL is not part of the manuscript, 
but a different contribution of radiation leakage can be expected between the two beamlines. 
The purpose of this work is to investigate the discrepancies between MC simulations and experimental 
dosimetry related to the X-ray interaction with the MSC. Radiochromic film dosimetry was used to 120 
quantify the parasitic radiation component due to the photons interaction with the inner walls of the MSC 
while MC simulations based on Geant4 (Agostinelli et al., 2003) were used to quantify the influence of the 
MSC radiation leakage into the valley region.  
2 MATERIALS AND METHODS 
2.1 Experimental setup at the ESRF ID17 Biomedical beamline 125 
2.1.1 Spectra definition 
The synchrotron radiation source at the ESRF ID17 Biomedical beamline is a wiggler of 1.5 m length and a 
magnetic field of 1.6 T at a gap of 24.8 mm. This is the typical configuration used for MRT experiments. 
The X-ray beam is transported mostly in vacuo up to the target that is placed around 40.5 m from the 
source point. A detailed description of the ID17 beamline can be found in several publications (Cornelius 130 
et al., 2014; Crosbie et al., 2015; Martínez-Rovira et al., 2012). Here, only the relevant information for the 
current study will be presented. 
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The X-ray spectrum generated by the wiggler was calculated with the XOP software version 2.3 (Del Río & 
Dejus, 2004). The spectrum at the target is modified due to the attenuation of several components in the 
beam path, for which the Beer-Lambert law was applied, and material attenuation coefficients from the 135 
NIST database (Hubbell & Seltzer, 1996) were taken. 
For this study, three different attenuation configurations were utilized. Configuration 1, or conventional 
MRT configuration, is the historically and originally used configuration for MRT experiments at ID17. 
Configuration 2, or pre-clinical MRT configuration, has been introduced to satisfy the request of having 
less dose deposition in dense tissues, such as bones, during veterinary pre-clinical studies. Compared to 140 
the conventional MRT configuration, the pre-clinical one presents a harder spectrum. The spectrum 
hardening is obtained by using different material and material thickness combination of five attenuators. 
This extra filtration produces an intrinsic reduction of the spectrum intensity as well. Configuration 3, or 
clinical MRT configuration, answers to more rigid safety rules that must be considered in a realistic clinical 
scenario where extra components such as krypton filters (Requardt et al., 2013) and ionization chambers 145 
must be added to monitor the beam during patient irradiation. While the energy characteristics of the 
clinical spectrum are close to the pre-clinical one, the clinical spectrum is further reduced in intensity due 
to the additional components added along the beam path.  
Table 1 reports the list of all the absorbers used to define the beam quality of the three MRT irradiation 
configurations.  150 
Table 2 presents the main characteristics of the three spectra.  
Figure 1 presents some properties and relations between the three spectra. Figure 1(A) shows the 
conventional MRT, pre-clinical MRT and clinical MRT X-ray energy spectra profiles impinging on the MSC 
and Figure 1(B) shows the corresponding profiles obtained after normalization to the maximum intensity, 
facilitating the recognition of the energy shift. Figure 1(C) presents the relative intensity difference of the 155 
pre-clinical and clinical normalized spectrum with respect to the conventional normalized spectra. The 
different attenuator combinations reduce the low energy part of the spectrum, below 90 keV, but they 
are not effective for energies above 100 keV. The weight contribution of photons with energies above 200 
keV is between 1.6 and 2.4 times more significant for pre-clinical and clinical spectra compared to the 




Table 1. List of beam intercepting components and their thickness for the three considered X-ray spectra 
configurations: conventional MRT, pre-clinical MRT and clinical MRT. 
  Configuration 1  Configuration 2 Configuration 3 












Be 2.3 Be 2.3 Be 2.3 
Attenuator rack         
Attenuator 1 C 1.15 C 1.42 C 1.42 
Attenuator 2 Al 0.28 Al 0.28 Al 0.28 
Attenuator 3 Al 1.24 Al 1.24 Al 1.24 
Attenuator 4 Cu 0.35 Cu 1.42 Cu 1.42 
Attenuator 5 Cu 0.69 Cu 0.69 Cu 0.69 






        
Windows not used   not used   Al 4 × 0.5 
Window coating not used   not used   Au 8 × ≈0.0001 
Exit window Al 0.5 Al 0.5 Al 0.5 
Ionization 
Chamber (IC0bis) 
not used   not used   PMMA 19 
 
Table 2. Mean energy and energy of the intensity maximum for the conventional, pre-clinical, and clinical 165 
MRT spectra. The last column presents the relative difference of the intensity maximum of the three 







Change of the intensity 
maximum compared to the 
Conventional configuration [%] 
Conventional 104.2 87.7 0% 
Pre-clinical 119.0 102.1 -48% 





Figure 1. (A) Plots of the three X-ray spectra profiles used in the study (conventional MRT, pre-clinical MRT 170 
and clinical MRT spectrum) normalized to the machine current and (B) corresponding spectrum profiles 
after normalization to the respectively maximum intensity value. (C) Plot of the relative differences of the 
pre-clinical and clinical normalized spectra compared to conventional spectrum.  
2.1.2 Multislit collimator 
The multislit collimator transforms the homogeneous field generated by the synchrotron source into a 175 
spatially fractionated array of radiation. For this study, the single stack MSC described in the work of E. 
Bräuer-Krisch et al. (Bräuer-Krisch et al., 2009) was used (see Figure 2). This MSC was made out of 125 
single tungsten carbide alloy plates because wire cutting techniques are not precise enough for machining 
apertures of less than 100 µm wide out of a single block. In this way, an array of 50 µm wide beams spaced 





Figure 2. Technical drawings of the single stack MSC used at the ESRF ID17 Biomedical beamline. Panel A 
shows the configuration used to assemble the single plates inside the metal frame (left); panel (B) reports 
the geometry of the water-cooling system (right). Courtesy of T. Brochard (ESRF). 185 
The metal base on which the MSC is mounted is fixed on a rotational stage able to align the apertures 
parallel to the beam with ±0.001° precision. A water-cooling system and a nitrogen gas flow impinging on 
the MSC avoid overheating during radiation exposures. The MSC is 8 mm thick and made of WF20 
tungsten-carbide alloy (supplier: JJ x-ray, Denmark) with density of 14.08 ± 0.01 g/cm3. The chemical 
material composition is reported in Table 3. 190 
Table 3. Material composition of the WF20 tungsten-carbide alloy in weight percentage (wt %). Table 
reported from E. Bräuer-Krisch et al. (Bräuer-Krisch et al., 2009). 
  WF20 chemical composition 
   WC  Co  VC + Cr3C2 
wt % 86.4 - 87.2 11.5 - 12.5 1.1 - 1.3 
 
The total attenuation coefficient of the MSC was calculated in the relevant photon range, 1 – 600 keV, 
using the NIST database (Hubbell & Seltzer, 1996). The percentage of transmitted radiation by the MSC 195 
was calculated following the Beer-Lambert law and it is reported in Figure 3(A). The metal blades 
effectively stop all photons with energies below 200 keV but allow the partial transmission of photons 
with energies above 200 keV. For comparison, the percentage of transmitted radiation by a 8 mm thick 
pure tungsten carbide (WC) MSC of density 15.63 g/cm³ and a pure tungsten (W) MSC of density of 19.3 
g/cm³ is as well reported in Figure 3(A). 200 
Figure 3(B) shows the expected spectra arising from the ID17 MSC due to radiation leakage. They were 
obtained, multiplying the normalized spectra of Figure 1(B) with the WF20 MSC radiation transmission 
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profile of Figure 3(A). Considering the normalized spectra impinging on the MSC for comparison, the 
leakage for the clinical spectrum is about a factor 2 higher than for the conventional spectrum. 
 205 
Figure 3. (A) X-ray transmission as a function of photon energy for the ID17 WF20 tungsten carbide alloy 
MSC compared to a MSC made out of tungsten carbide (WC) or pure tungsten (W). (B) Expected X-ray 
spectra arising from the incomplete absorption of the ID17 MSC metal blades, obtained multiplying each 
spectrum profile of Figure 1(B) by the WF 20 MSC transmission curve of Figure 3(A). 
2.2 Film dosimetry for quantification of the radiation interaction with the multislit 210 
collimator inner walls 
Radiochromic films are well known detectors in radiation therapy, able to visualize the 2-dimensional dose 
distribution of the irradiated area. The detailed description of the protocol developed for MRT film 
dosimetry at micrometric scale and used in this work is documented  in the literature (Pellicioli et al., 
2019). Here, only the specific irradiation setup and geometry used in the study will be presented.  215 
Prior to film irradiation, absolute dosimetry under reference conditions was performed following the 
protocol presented by Fournier et al. (Fournier, Crosbie et al., 2016), following as close as possible the 
recommendations of the International Atomic Energy Agency - IAEA - for reference dosimetry using 
medium energy kilovoltage X-rays (Musolino & IAEA TRS-398, 2001). Due to the limited vertical dimension 
of the synchrotron beam (see Introduction), a PTW PinPoint 31014 ionization chamber was scanned 220 
through the beam to evaluate the beam dose rate. Reference dosimetry was performed in a water-
equivalent plastic cubic phantom placing the ionization chamber in the center of the scanned 20 × 20 mm2 
broad beam field and with its central axis at 20 mm depth. Radiochromic films (Gafchromic™ HD-V2 type) 
were irradiated under the same reference conditions for the definition of the calibration curve between 
0 Gy (non-irradiated film) and 250 Gy, the dose-range of interest for the study. 225 
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Following the film calibration, microbeam irradiations were performed placing and aligning the MSC inside 
the beam. Three radiation fields were defined with a size of 5 × 5 mm2, 10 × 10 mm2 and 20 × 20 mm2 as 
array of 50 µm wide beams with a pitch of 400 µm. A single film irradiation was performed for each field 
size at 5 mm, 10 mm, 20 mm, 30 mm, 50 mm and 80 mm depth in the water-equivalent phantom. Films 
were scanned with an optical microscope 10 days after exposition, following the protocol presented by 230 
Pellicioli et al. (Pellicioli et al., 2019). The dose profile of the five central valleys was considered for each 
microbeam array and dose values were integrated over the central 50 µm wide region. The uncertainty 
related to the relative comparison between valley doses on a single piece of film is due to the microscopic 
non-homogeneity that a radiochromic film may present over a 2 × 2 mm² of area considered in this study. 
For dose values integrated over the defined valley regions, the uncertainty was found to be 1.52% (2σ). 235 
As the uncertainty value is small, it is not reported in the section 3.1 to facilitate data visualization. 
2.3 Monte Carlo simulations for radiation leakage study 
The investigation of the radiation leakage through the MSC metal blades was performed with MC radiation 
transport simulations, implemented with Geant4 toolkit version 10.03.p03 using the Penelope physics 
models (Agostinelli et al., 2003; Salvat et al., 2009). Two scenarios were considered. The first represents 240 
the ideal case of a perfect array of parallel microbeams without any radiation contribution due to radiation 
leakage in the MSC. The second mimics a more realistic irradiation setup, where an ideal broad beam of 
photons generated at the wiggler source position with the X-ray energy spectrum as described in section 
2.1.1 is impinging on the MSC. In this case, the radiation leakage in the MSC is taken into account and all 
the photons that are not absorbed by the MSC are considered for the calculation of the dose inside the 245 
target. 
A water equivalent phantom of 100 × 100 × 100 mm3 was used as target. Three radiation fields of 5 × 5 
mm2, 10 × 10 mm2 and 20 × 20 mm2 were defined as an array of 50 µm wide beams of 400 µm pitch. The 
three different X-ray energy spectra (conventional MRT, pre-clinical MRT and clinical MRT) defined in 
section 2.1.1 were considered. The dose evaluation was performed as an average dose of five central 250 
peaks and four central valleys of each array, considering a 10 µm central region for each peak and a 50 
µm region for each valley. Vertically, along the scanning direction, a 100 µm region was considered in the 
center of the field. The depth dose profile was studied with a spatial resolution of 1 mm inside the 
phantom (along the beam propagation direction). 
To provide a reliable micrometric dose scoring due to the spatial fractionation at micrometric scale of the 255 
radiation field, the production threshold for secondary particles was defined as 1 µm while the maximum 
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step size for electron propagation was set to 5 µm. The total number of simulated photons was adjusted 
for each simulation in order to achieve a density of 1.6 × 106 photons/µm2 inside the microbeam region 
as well as impinging on the MSC in the more realistic scenario. The simulation statistical uncertainties for 
the total considered regions were found to be less than 0.04% (2σ) and 0.27% (2σ) for the peak and valley 260 
dose, respectively. As the uncertainty values are very small, they are not reported in the section 3.2 to 
facilitate data visualization. 
To further extend the work, MC simulations were performed to evaluate the effect of different MSC 
materials in terms of radiation leakage. The case of a pure tungsten carbide (WC) alloy and pure tungsten 
(W) as defined in section 2.1.2 was chosen, and depth dose profiles were calculated for the three field 265 
sizes and spectra mentioned above. 
3 RESULTS 
3.1 Photon interaction on the inner walls of the multislit collimator 
Figure 4 presents four dose profiles evaluated with the radiochromic films at 5 mm, 20 mm, 50 mm, 80 
mm depth inside the phantom for the case of a 5 × 5 mm2 array. It is possible to recognize a pattern of 270 
“regular” and “distorted” valleys at all measured depths. This pattern arises from the presence of a 
radiation contribution in the valley regions due to photons interacting with the inner surfaces of the MSC. 
Regular valleys have a symmetrical and rounded profile, as expected, while distorted valleys present an 
additional parasitic radiation contribution on one or both sides, corresponding to an irregular profile 
characterized by a higher dose. Regular valleys are marked with a blue dot while distorted valleys are 275 
marked with a red cross. The same pattern is visible for all the profiles. The same phenomenon is also 




Figure 4. Valley dose profile of a 5 × 5 mm² microbeam field at different depths. The repetitive pattern 
between regular and distorted valley shapes is identified by blue dots and red crosses, respectively. All the 280 
dose profiles have been normalized to the minimum dose value of the central valley, in this case a distorted 
one. 
After the visual classification of the valleys, the five central valleys of each irradiated field were 
considered, and the average dose value was calculated for each regular and distorted valley group. Figure 
5 shows the relative dose variation of the distorted valleys with respect to the regular ones and Table 4 285 
reports the relative increase of the dose. The contribution of photons interacting with the MSC walls is 
more significant for a small field size than for large ones. The amount of parasitic radiation is a constant 
fraction of the peak dose, while the dose deposited into valley regions due to photon scattering inside the 
phantom is smaller for small field size. Consequently, the additional dose contribution is more significant 
in a small field. The proposed linear fit for the three series of data of Figure 5 suggests also that, for large 290 
fields, the dose difference between distorted and regular valleys tends to decrease moving deeper inside 




Figure 5. Relative dose variation of regular and distorted valleys for three different field sizes and at 
different depths in the phantom. Five central valleys of each field were considered. The linear fits are guides 295 
to the eye. 
Table 4. Relative dose variation of distorted valleys with respect to regular valleys for three different field 
sizes. 
Field size Relative dose variation [%] 
5 × 5 mm² 12.5% – 16.0%  
10 × 10 mm² 7.5% – 10.5%  
20 × 20 mm² 3.0% - 8.0%  
 
3.2 Radiation leakage through the multislit collimator blades 300 
MC simulations indicate that the extra peak dose contribution due to the radiation leakage through the 
MSC blades for the three different field sizes, the three different spectrum configurations, and at all 
phantom depths is, on average, equal to 0.2%, with variations between 0.1% and 0.3% due to statistical 
fluctuations.  
By contrast, valley doses are significantly affected by the radiation leakage contribution. Figure 6 presents 305 
an overview of valley depth dose profiles and related PVDRs for the three field sizes and the conventional 
MRT spectrum. Similar trends are obtained using the pre-clinical and clinical spectrum.  
Figure 7 presents the valley dose and PVDR relative variation between simulations without and with 
radiation leakage. Focusing on the data at 20 mm depth, where reference dosimetry is performed, around 
5% valley dose increase is occurring for the 20 × 20 mm² field, 10% for the 10 × 10 mm² field and 18% for 310 
the 5 × 5 mm² field using the conventional spectrum. Using the clinical spectrum, around 10% valley dose 
increase occurs for the 20 × 20 mm² field, 17% for the 10 × 10 mm² field and 30% for the 5 × 5 mm² field. 
An intermediate case is obtained when the pre-clinical MRT spectrum is used for irradiations. Even more 
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significant differences are observed at the phantom surface where the relative dose increase is about 
twice as high as at 20 mm depth. PVDRs are consequently affected and an overall reduction is observed 315 
at all phantom depths. Again, PVDR reduction is stronger for small fields. 
 
Figure 6. Influence of the MSC leakage for different field sizes and the conventional MRT spectrum. Panel 






Figure 7. Influence of the MSC leakage for different field sizes, reported as relative change of the valley 
depth dose profile (left panels) and of PVDR values (right panels) without and with radiation leakage. Panel 
A and B (top): conventional MRT spectrum; Panel C and D (center) pre-clinical MRT spectrum; Panel E and 325 
F (bottom) clinical MRT spectrum. 
Comparing PVDRs for a fixed field size and considering the three different spectra, the use of the clinical 
MRT spectrum may not be the most effective solution to increase PVDR values. In fact, for the 5 × 5 mm² 
field the PVDRs obtained from simulations using the clinical MRT spectrum and including the MSC leakage 
are lower than the ones obtained with the conventional MRT spectrum. The PVDR reduction is around 5% 330 
at 20 mm depth and 10% at the phantom surface. When considering the 10 × 10 mm² field the use of 
harder spectra has a negligible impact on PVDR values compared to the conventional MRT spectrum at 20 
mm depth. The advantage of using the pre-clinical or clinical MRT spectrum is visible for the 20 × 20 mm² 
field where PVDR values are 5% higher at 20 mm depth and 2% at the phantom surface. 
The small fraction of photons directly impinging on the MSC but not absorbed inside the metal become 335 
primary photons for the valley region contributing with an extra dose deposition. The amount of leakage 
radiation is a constant fraction of the radiation impinging on the MSC absorbers, while the dose deposited 
into valley regions due to photon scattering inside the phantom is smaller for a small field size, as already 
mentioned in section 3.1. Also in this case, the additional dose contribution is more significant in a small 
field. Moreover, the radiation scattering contribution inside the phantom close to its surface is smaller 340 
than in the center; therefore, any external dose contribution is more significant at the phantom’s 
entrance, as visible in the relative variation of the valley dose with depth (see Figure 7). 
3.3 Analysis of alternative materials for a novel multislit collimator 
With the purpose to decrease the contribution of leakage radiation into valley regions, WC alloy and pure 
W were studied in dedicated Geant4 simulations as possible alternative to the WF20 alloy of the ID17 345 
MSC. Peak and valley depth dose profiles and the corresponding PVDRs were calculated for different field 
sizes and MRT spectra. 
As expected, peak doses are minimally affected using different MSCs. On the contrary, valley doses change 
significantly. Figure 8 presents the depth dose variation for a 5 × 5 mm² radiation field of the clinical MRT 
spectrum considering the three different MSCs and comparing them with the ideal case of complete 350 
absence of radiation leakage defined in section 2.3. It is clearly visible in Figure 8(A) that the use of a pure 




Figure 9 presents the valley dose and PVDR relative variation between simulations without and with 
radiation leakage for different MSC materials, using the clinical spectrum. For a 5 × 5 mm² field, the valley 355 
dose at 20 mm depth is increased by 6% using a MSC made of W, while it is increased by 30% using the 
WF20 material. The reduction by a factor of 5 of the relative dose variations is almost constant at all 
depths inside the phantom, and PVDRs reflect the same trend. In the case of a 20 × 20 mm² field, the 
remaining leakage contribution of radiation using a MSC made of W increases valley doses no more than 
2% inside the phantom and no more than 4% close to the surface. These values are around 5 times lower 360 
compared to the use of a MSC made of WF20. Table 5 summarizes the valley dose and PVDR relative 
variation between simulations without and with radiation leakage considering the three field sizes, 
spectrum configurations and MSC materials. Values at 1 mm depth were considered to highlight the 
maximum variations occurring close to the surface of the phantom; values at 20 mm depth were 
considered because reference dosimetry in MRT is performed at this position.  365 
 
Figure 8. Influence of different MSC materials on the radiation leakage for a 5 × 5 mm² field, using the 
clinical spectrum. Panel A and B report the valley depth dose profile (left) and PVDR values (right) without 





Figure 9. Influence of different MSC materials on the radiation leakage using the clinical spectrum. Left 
panels report the relative change (without and with radiation leakage) of the valley depth dose profile, 
right panels the PVDR values. Panel A and B (top): 5 × 5 mm² field; panel C and D (bottom): 20 × 20 mm² 
field. 375 
Table 5. Valley dose and PVDR relative variation between simulations without and with radiation leakage 
considering the three different spectrum configurations and MSC materials. Simulations without radiation 
leakage were chosen as reference data set. For each of the three field sizes, variations at 1 mm and 20 mm 
depth are reported. 
 Conventional spectrum 
 Valley dose PVDR 
MSC 
material 
5 × 5 mm² field 10 × 10 mm² field 20 × 20 mm² field 5 × 5 mm² field 10 × 10 mm² field 20 × 20 mm² field 
1 mm* 20 mm* 1 mm 20 mm 1 mm 20 mm 1 mm 20 mm 1 mm 20 mm 1 mm 20 mm 
WF20 28% 17% 18% 10% 11% 6% -22% -15% -15% -9% -10% -5% 
WC 14% 9% 9% 5% 6% 3% -13% -9% -8% -5% -5% -3% 
W 5% 3% 3% 2% 2% 1% -5% -3% -3% -2% -2% -1% 
 Pre-clinical spectrum 
WF20 43% 25% 27% 14% 17% 8% -30% -20% -21% -12% -14% -8% 
WC 22% 13% 14% 7% 9% 4% -18% -12% -12% -7% -8% -4% 
W 9% 5% 6% 3% 3% 2% -8% -5% -5% -3% -3% -2% 
 Clinical spectrum 
WF20 50% 30% 32% 17% 20% 10% -33% -23% -24% -14% -16% -9% 
WC 26% 16% 17% 9% 11% 5% -20% -13% -14% -8% -9% -5% 
W 10% 6% 7% 4% 4% 2% -9% -6% -6% -4% -4% -2% 
             





The production of an array of beams spatially fractionated at the micrometer scale using an MSC causes 
the presence of different interactions between X-ray photons and the metal, and these may significantly 
impact the irradiation results. Ideally, a MSC should completely stop the radiation impinging on its metal 
blades and only transmit unperturbed photons through the apertures. Actually, photons interacting with 385 
the inner walls of the MSC may undergo scattering and also, some photons may be transmitted through 
the metal blades. In both cases, dose distributions inside the target are affected by these factors and they 
must be considered during dose calculation and experimental dosimetry. 
Characterization of the surface roughness of the MSC inner walls should be the first factor to consider and 
be included in the description of the radiation interaction with the metal surface. In addition, even if the 390 
MSC is optimally aligned before each experimental session, sub-micrometric misalignment of the metal 
blades during the collimator manufacture may as well influence these interactions. These phenomena 
require a detailed study to understand and quantify separately the different factors. Radiochromic film 
dosimetry is an effective approach to recognize and evaluate the total extra contribution of dose 
presented in “distorted” valleys. Current MC simulations are considering photon scattering from perfectly 395 
smooth and parallel inner walls of the MSC. Under these conditions, only measured “regular” valley dose 
must be compared to simulated dose during benchmarks. 
The second factor able to significantly affect valley dose values is the radiation leakage through the MSC 
metal blades. The WF20 tungsten carbide alloy of the actual ID17 MSC is able to absorb efficiently photons 
with energies below 200 keV but the spectra used for MRT irradiations have a component above this 400 
energy that is partially transmitted, thus increasing the valley dose. When using small field sizes in the 
order of 5 × 5 mm² in combination with the clinical MRT spectrum, the valley dose is increased by 30% - 
50%. MSC radiation leakage must therefore always be included and accurately implemented in MC 
simulations. 
Radiation leakage could be reduced by using a thicker MSC. This, however, leads to a larger inner wall 405 
surface interacting with photons, thus increasing the possibility of photon scattering. Furthermore, such 
a MSC is more sensitive to small misalignments of the individual blades, which in turn lead to variations 
in the microbeam width. The use of an alternative material is the preferred choice. A pure tungsten MSC 
effectively absorbs photons up to 300 keV and drastically reduces radiation leakage. This solution is 
currently considered for the ID17 Biomedical beamline.  410 
20 
 
It is worth to mention that, at the moment of the preparation of this study, the phantom dimension was 
chosen to be similar to the dimension used by different research groups (Day et al., 2020; Dipuglia et al., 
2019). Even if this geometry may not correspond to a realistic clinical scenario, the phantom is adequate 
to answer to the scientific question subject of this work. Steep dose variations for valley regions are more 
significant at the entrance and exit of the phantom, where the contribution of the scattered radiation is 415 
weaker, and these are well visible in the figures presented in the results. The equivalence between 
simulated and experimental volumes was well respected to obtain a correct comparison of dosimetry 
data, but for more clinically relevant studies a cubic phantom of 20 cm width and length should be the 
preferable solution. 
The datasets presented in this work are valid for some specific MRT configurations but provide valuable 420 
general guidelines for any MRT setup and the associated dosimetry protocols. Experimental valley doses 
at ID17 were typically higher than MC calculated values and most of the discrepancy is explained by the 
factors quantified in this work. A first comparison between previously irradiated film and the updated MC 
simulation confirms the improvements of the MC model for the pre-clinical scenario and the use of a 20 
× 20 mm² field. Table 6 presents values such as peak and valley output factor with respect to reference 425 
conditions as described in section 2.2.  In the same table, PVDR values are as well reported. The agreement 
is in average better than 5%, close to the agreement required for clinical applications that is typically in 
the order of 3%. This is an encouraging starting point and a more exhaustive and complete benchmarking 
of experimental dosimetry against simulated dose is already scheduled.  
Table 6. Output factor (OF) and PVDR values for MC simulation and radiochromic film dosimetry obtained 430 
using the pre-clinical scenario and a 20 × 20 mm² field. 
Depth 
[mm] 










20 0.722 0.711 -1.6 0.0260 0.0266 2.4 27.8 26.7 -3.8 
40 0.528 0.500 -5.3 0.0220 0.0217 -1.7 23.9 23.1 -3.6 
60 0.385 0.367 -4.8 0.0172 0.0168 -2.0 22.4 21.8 -2.9 





The photon interaction with a MSC for the generation of microbeams is a key point for the reliable 
definition of applications in radiotherapy. An ideal model where all photons impinging on the metal blades 435 
of an MSC are absorbed and do not reach the target is a too strong approximation and must not be used 
in simulated dose calculations. 
Considering the most recent studies in MRT performed at ID17, a detailed analysis of the factors 
influencing dose distribution in the target related to photon-MSC interactions was performed. The 
contribution of radiation interaction with the inner walls of the MSC and radiation leakage through the 440 
absorber was characterized for three different field sizes and three different X-ray spectra. Small fields of 
5 × 5 mm² are strongly affected by both factors because the weak scattered dose between microbeams is 
comparable with the parasitic dose contribution.  
The use of harder and less intense spectra as defined for clinical trials leads to significant radiation leakage 
as well for 20 × 20 mm² fields. The WF20 tungsten carbide blades of the ID17 MSC do not sufficiently 445 
absorb photons with energies above 200 keV and other materials should be considered.  
The quantification of the dose contributions due to the X-ray radiation interaction with the MSC is 
fundamental and it supports the definition of more reliable dosimetry protocols for MRT, facilitating a 
precise benchmarking of experimental dose values against simulated dose values. 
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